Invention Grant
US08900600B2 Identification, optimization and use of cryptic HLA-A24 epitopes for immunotherapy
有权
鉴定，优化和使用隐匿性HLA-A24表位进行免疫治疗
- Patent Title: Identification, optimization and use of cryptic HLA-A24 epitopes for immunotherapy
- Patent Title (中): 鉴定，优化和使用隐匿性HLA-A24表位进行免疫治疗
-
Application No.: US13258227Application Date: 2009-04-02
-
Publication No.: US08900600B2Publication Date: 2014-12-02
- Inventor: Kostantinos (Kostas) Kosmatopoulos , Jeanne Menez-Jamet
- Applicant: Kostantinos (Kostas) Kosmatopoulos , Jeanne Menez-Jamet
- Applicant Address: FR Paris
- Assignee: VAXON Biotech
- Current Assignee: VAXON Biotech
- Current Assignee Address: FR Paris
- Agency: Morgan, Lewis & Bockius LLP
- International Application: PCT/IB2009/005753 WO 20090402
- International Announcement: WO2010/112962 WO 20101007
- Main IPC: C07K7/06
- IPC: C07K7/06 ; C07K4/12 ; C07K2/00 ; A61K38/03 ; A61K39/21 ; C07K14/005 ; A61K39/00 ; A61K38/00
Abstract:
The present invention discloses peptides such as an isolated peptide consisting of an immunogenic HLA-A*2402-restricted epitope. For example, the isolated peptide may be selected from the group consisting of KYGVLLKTL (SEQ ID NO:11); RYMRQFVAL (SEQ ID NO: 12); RYVSRLLGI (SEQ ID NO: 13); RYGKGWDLL (SEQ ID NO: 14); RYLVQVQAL (SEQ ID NO: 15); and RYWELSNHL (SEQ ID NO: 16).
Public/Granted literature
- US20120082692A1 Identification, Optimization and Use of Cryptic HLA-A24 Epitopes for Immunotherapy Public/Granted day:2012-04-05
Information query
